Home » Stocks » BCDA

BioCardia, Inc. (BCDA)

Stock Price: $4.39 USD 0.18 (4.28%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $4.38 -0.01 (-0.23%) Jan 21, 7:58 PM
Market Cap 61.78M
Revenue (ttm) 314,000
Net Income (ttm) -15.52M
Shares Out 12.62M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $4.39
Previous Close $4.21
Change ($) 0.18
Change (%) 4.28%
Day's Open 4.30
Day's Range 4.20 - 4.50
Day's Volume 471,381
52-Week Range 1.92 - 6.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

SAN CARLOS, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, welcome...

Benzinga - 3 weeks ago

Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B....

Other stocks mentioned: ALT, INCY
GlobeNewsWire - 3 weeks ago

Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Structural Heart Procedures Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia...

GlobeNewsWire - 1 month ago

SAN CARLOS, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announce...

Market Watch - 1 month ago

Shares of BioCardia Inc. sank 13.9% in morning trading Wednesday, after the developer of regenerative biologic therapies announced more stock sales in the wake of the 137.6% rocket ride over t...

GlobeNewsWire - 1 month ago

SAN CARLOS, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA) (BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for ...

GlobeNewsWire - 1 month ago

SAN CARLOS, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for t...

GlobeNewsWire - 1 month ago

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for t...

InvestorPlace - 1 month ago

BioCardia (BCDA) news for Monday includes an announcement concerning interim clinical trial results boosting BCDA stock higher. The post BioCardia News: Why BCDA Stock Is Soaring Today appeare...

Benzinga - 1 month ago

BioCardia (NASDAQ: BCDA) shares are trading higher. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Fa...

Other stocks mentioned: HCA, PACB
GlobeNewsWire - 1 month ago

SAN CARLOS, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] today announced that the Company's proprietary Helix Biotherapeutic Delivery System (the Helix System) dem...

GlobeNewsWire - 2 months ago

SAN CARLOS, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of autologous and allogenic cell therapies, today reported financial results ...

GlobeNewsWire - 2 months ago

Paper P ublished in International Journal of Cardiology D emonstrates S afety and T olerability W hile S howing F unctional I mprovement at S ix M onths

GlobeNewsWire - 3 months ago

Technology May Enable Same-Day Outpatient Cell Therapy Procedures Technology May Enable Same-Day Outpatient Cell Therapy Procedures

GlobeNewsWire - 4 months ago

SAN CARLOS, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies toda...

GlobeNewsWire - 5 months ago

SAN CARLOS, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...

Zacks Investment Research - 5 months ago

BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 5 months ago

SAN CARLOS, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, toda...

GlobeNewsWire - 6 months ago

First Site Initiation Visit in Trial Completed and Executive Steering Committee Named First Site Initiation Visit in Trial Completed and Executive Steering Committee Named

GlobeNewsWire - 6 months ago

SAN CARLOS, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today...

GlobeNewsWire - 7 months ago

SAN CARLOS, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  NasdaqCM: BCDA (the “Company”), a leader in the development of comprehensive solutions for cardiovascular regenerativ...

GlobeNewsWire - 8 months ago

SAN CARLOS, Calif., May 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, toda...

GlobeNewsWire - 8 months ago

SAN CARLOS, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, toda...

GlobeNewsWire - 8 months ago

SAN CARLOS, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today ...

GlobeNewsWire - 1 year ago

SAN CARLOS, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today ...

About BCDA

BioCardia, a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneou... [Read more...]

Industry
Biotechnology
CEO
Peter Altman
Employees
20
Stock Exchange
NASDAQ
Ticker Symbol
BCDA
Full Company Profile

Financial Performance

In 2019, BioCardia's revenue was $710,000, an increase of 13.60% compared to the previous year's $625,000. Losses were -$14.71 million, 5.16% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for BioCardia stock is "Buy" and the 12-month stock price forecast is 12.88.

Price Target
$12.88
Analyst Consensus: Buy